pharmaphorum

JUNE 8, 2021

All these factors will support the growth of in-house R&D-driven pharmaceutical companies and bring more innovative drugs to Asian markets.”. Dr Jay Mei has nearly 30 years of experience in clinical research and development of oncology therapeutics globally. Chemotherapy still accounted for 72.6%

Chemotherapy 105

Chemotherapy Pharmaceutical Companies Pharmaceutical Companies Immunity 105

Pharmaceutical Technology

FEBRUARY 13, 2023

The first concept for a PROTAC was published in 2001, and recently these protein degraders have gained rapid momentum as a promising novel modality. However, on-target adverse events are also common with BTKis as they inhibit B-cell immune responses, which can result in serious infections.

Dosage 59

Dosage Chemotherapy Compounding Immunity 59

PharmaShots

FEBRUARY 21, 2023

Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. The company is developing PPMX-T002, an anti-cancer drug with an antibody targeting CDH3 connected with a radioisotope yttrium 90 (90Y).

Dosage 56

Dosage Labelling Immunity Immunization 56

Pharmaceutical Technology

FEBRUARY 20, 2023

On the other hand, a lack of diversity in clinical trial populations, particularly when the disease population is significantly underrepresented, greatly diminishes the quality of data obtained for drug safety and efficacy profiles. This may sound obvious, but it is still a major hurdle in drug development.

Vaccines 52

Vaccines Communication Immunity Immunization 52